<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260514069400N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-09</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Elvatan k5+ for treatment of melasma</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effect of Elvatan k5+ for treatment of melasma</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/90989</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible participants will be randomly allocated into two equal groups (1:1 allocation ratio) using permuted block randomization with variable block sizes of 4 and 6 [یا: fixed block size of 4]. The random allocation sequence will be generated prior to participant enrollment by an independent researcher using Random Allocation Software (Version 2.0, developed by M. Saghaei, Isfahan University of Medical Sciences, available at: https://mahmoodsaghaei.tripod.com/Softwares/randalloc.html). To ensure allocation concealment, sequentially numbered, opaque, sealed envelopes (SNOSE) will be utilized. Each envelope, containing the assigned intervention code, will be opened sequentially by an independent coordinator only after participant enrollment and baseline clinical evaluation, Blinding description: This study will be conducted as a double-blind clinical trial. K5+ Elvatan cream and topical tranexamic acid cream will be placed in identical containers in terms of shape, color, and size and will be labeled as Drug A and Drug B. Participants and the treating/evaluating physicians will be blinded to the allocated intervention, and only the pharmacist will be aware of the contents of each code.</study_design>
      <phase>3</phase>
      <hc_freetext>melasma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: participants in the intervention group receive K5+ Elvatan cream, applied twice daily, in the morning and evening, to the melasma-affected areas. The duration of intervention is three months. Participants are evaluated at baseline, one month after treatment initiation, and three months after treatment initiation for melasma severity, quality of life, and possible adverse drug effects. Intervention 2: Control group: participants in the control/comparator group receive topical tranexamic acid cream, applied twice daily, in the morning and evening, to the melasma-affected areas. The duration of intervention is three months. Participants are evaluated at baseline, one month after treatment initiation, and three months after treatment initiation for melasma severity, quality of life, and possible adverse drug effects.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data (including demographic and clinical outcomes).

When:
Access period starts 6 months after results are published.

To whom:
It will be available to researchers working in academic and scientific institutions.

Conditions:
Strictly for meta-analysis or scientific validation, after signing a data-use and confidentiality agreement.

Where to obtain:
Latifeh Habibi

How to obtain:
Formal email request from the applicant -&gt; Review by the research team -&gt; University Ethics Committee approval (if required) -&gt; Data sharing via secure email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Latifeh Habibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>zand street</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۳۴۸۴۶۱۱۴</zip>
        <telephone>+98 71 3235 1099</telephone>
        <email>latifahabibi92@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Latifeh Habibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>zand street</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۷۱۳۴۸۴۶۱۱۴</zip>
        <telephone>+98 71 3235 1099</telephone>
        <email>latifahabibi92@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients between 18-60 years old with a diagnosis of melasma
not been treated with skin lightening agents in the past three  months.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnant women
breastfeeding women
chronic renal failure and end-stage renal disease
cirrhosis and end-stage liver disease
autoimmune disorders such as systemic lupus erythematosus
previous history of deep vein thrombosis or pulmonary thromboembolism in the patient or their family members
unwillingness to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L81.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chloasma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: participants in the intervention group receive K5+ Elvatan cream, applied twice daily, in the morning and evening, to the melasma-affected areas. The duration of intervention is three months. Participants are evaluated at baseline, one month after treatment initiation, and three months after treatment initiation for melasma severity, quality of life, and possible adverse drug effects.</i_keyword>
      <i_keyword>Control group: participants in the control/comparator group receive topical tranexamic acid cream, applied twice daily, in the morning and evening, to the melasma-affected areas. The duration of intervention is three months. Participants are evaluated at baseline, one month after treatment initiation, and three months after treatment initiation for melasma severity, quality of life, and possible adverse drug effects.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in Melasma Area and Severity Index (MASI) score. Timepoint: Baseline, one month after treatment initiation, and three months after treatment initiation. Method of measurement: MASI score will be assessed by a dermatologist/trained evaluator based on darkness, homogeneity, and area of facial involvement.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Change in the darkness of melasma lesions. Timepoint: Baseline, one month after treatment initiation, and three months after treatment initiation. Method of measurement: The darkness of melasma lesions will be assessed and recorded using Visioface imaging system.</sec_outcome>
      <sec_outcome>Change in dermatology-related quality of life. Timepoint: Baseline, one month after treatment initiation, and three months after treatment initiation. Method of measurement: Patients’ quality of life will be assessed using the Persian version of the Dermatology Life Quality Index (DLQI) questionnaire.</sec_outcome>
      <sec_outcome>Change in melasma-specific quality of life. Timepoint: Baseline, one month after treatment initiation, and three months after treatment initiation. Method of measurement: Melasma-specific quality of life will be assessed using the Persian version of the Melasma Quality of Life (melasQOL) questionnaire.</sec_outcome>
      <sec_outcome>Global assessment of treatment response by patient and physician. Timepoint: One month after treatment initiation and three months after treatment initiation. Method of measurement: Treatment response will be assessed by the patient and two dermatologists using a five-point Likert scale ranging from -2, indicating significant worsening, to +2, indicating significant improvement. In case of disagreement, the opinion of the attending dermatologist will be recorded as the final assessment.</sec_outcome>
      <sec_outcome>Occurrence of possible drug-related adverse effects. Timepoint: Throughout the treatment period, one month after treatment initiation, and three months after treatment initiation. Method of measurement: Possible adverse effects will be recorded through patient history, clinical examination, and an adverse-effect checklist, including redness, itching, burning, skin irritation, dryness, hypersensitivity, or any other patient-reported adverse effects.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-07-22</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand strret shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
